Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study.
暂无分享,去创建一个
Sudha Seshadri | Ralph B D'Agostino | Douglas P Kiel | D. Kiel | R. D'Agostino | P. Wolf | A. Beiser | P. Wilson | S. Seshadri | Alexa Beiser | Philip A Wolf | Z. Tan | Zaldy Sy Tan | Peter W F Wilson | Michael Tocco | M. Tocco
[1] P. Mcgeer,et al. The importance of inflammatory mechanisms in alzheimer disease , 1998, Experimental Gerontology.
[2] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[3] K. Hall,et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer’s disease: A population-based study of African Americans , 2000, Neurology.
[4] H Jick,et al. Statins and the risk of dementia , 2000, The Lancet.
[5] R. D'Agostino,et al. Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. , 1997, The New England journal of medicine.
[6] L. Berg. Clinical Dementia Rating (CDR). , 1988, Psychopharmacology bulletin.
[7] E. Boerwinkle,et al. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. , 1991, American journal of human genetics.
[8] J. Albers,et al. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. , 1982, Clinical chemistry.
[9] K. Anderson,et al. Determinants of change in total cholesterol and HDL-C with age: the Framingham Study. , 1994, Journal of gerontology.
[10] R B D'Agostino,et al. The effect of education on the incidence of dementia and Alzheimer's disease in the Framingham Study , 1995, Neurology.
[11] A. Hofman,et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study , 1997, The Lancet.
[12] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[13] B. Brodie,et al. A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. , 1952, The Journal of biological chemistry.
[14] P. Amouyel,et al. Interactions between Apolipoprotein E and Apolipoprotein(a) in Patients with Late-Onset Alzheimer Disease , 2000, Annals of Internal Medicine.
[15] Blood lipid measurements: Variations and practical utility , 1992, JAMA.
[16] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[17] P. Wilson,et al. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[18] G. Celesia,et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.
[19] E. Kaplan,et al. Neuropsychological test performance in Framingham: a descriptive study. , 1987, Psychological reports.
[20] M. Linton,et al. Current perspectives on statins. , 2000, Circulation.
[21] B. Strooper,et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[22] R B D'Agostino,et al. Incidence of dementia and probable Alzheimer's disease in a general population , 1993, Neurology.
[23] R. Laaksonen,et al. Low-density lipoprotein-independent effects of statins. , 1999, Current opinion in lipidology.
[24] M. Emmerling,et al. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. , 1998, Biochemical and biophysical research communications.
[25] Stephen W. Scheff,et al. Induction of Alzheimer-like β-Amyloid Immunoreactivity in the Brains of Rabbits with Dietary Cholesterol , 1994, Experimental Neurology.
[26] B. Hyman,et al. Role of the low-density lipoprotein receptor-related protein in beta-amyloid metabolism and Alzheimer disease. , 2000, Archives of neurology.
[27] M. Kergoat,et al. Anthropometric changes over 5 years in elderly Canadians by age, gender, and cognitive status. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.
[28] P. Wilson,et al. Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms. , 1987, Journal of lipid research.
[29] D. Sparks,et al. Temporal Sequence of Plaque Formation in the Cerebral Cortex of Non-Demented Individuals , 1993, Journal of neuropathology and experimental neurology.
[30] R. Mayeux,et al. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly , 1999, Neurology.
[31] P. Wilson,et al. Frequency of ApoB and ApoE gene mutations as causes of hypobetalipoproteinemia in the framingham offspring population. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[32] A. Demchuk,et al. HMG-CoA reductase inhibitors (statins) , 2000, Neurology.
[33] A. Nissinen,et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. , 1998, Neuroepidemiology.